← All trials
NCT02241616
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2014
- Primary completion
- Dec 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 350
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Shanghai University of Traditional Chinese MedicineLead sponsor
- Shanghai University of Traditional Chinese MedicineReponsible party - principal investigator
- Shenzhen Third People's HospitalCollaborator
- The Fifth People's Hospital of SuzhouCollaborator
- Capital Medical UniversityCollaborator
- Peking UniversityCollaborator
- Fudan UniversityCollaborator
- Huai'an No. 4 People's HospitalCollaborator
- Fifth Hospital of Shijiazhuang CityCollaborator
- China Academy of Chinese Medical SciencesCollaborator
- Guangxi Medical UniversityCollaborator
- Shandong University of Traditional Chinese MedicineCollaborator
- Nanchang UniversityCollaborator
- Hubei University of Chinese MedicineCollaborator
- Ningxia Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Henan Medical UniversityCollaborator
- Shanghai University of Traditional Chinese MedicineStudy director
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.